Advertisement
Advertisement
June 28, 2012
Aptus Endosystems to Pursue Expanded Use of Its EVAR Devices
June 27, 2012—Aptus Endosystems, Inc. (Sunnyvale, CA) announced that with the closing of a $25 million equity financing agreement, the company will expand commercialization of the HeliFX aortic securement system in the United States and Europe and further develop HeliFX products for the treatment of aortic aneurysms. The securement system has received US Food and Drug Administration (FDA) clearance and CE Mark approval.
In a press release, the company also stated that it plans to execute a United States clinical trial of the Fortevo abdominal aortic aneurysm endograft system in support of filing for premarket approval with the FDA, and to expand commercialization of the device in Europe, where it has CE Mark approval.
Advertisement
Advertisement
